Progress of lymphoid-specific tyrosine phosphatase inhibitors
10.16438/j.0513-4870.2017-0084
- VernacularTitle:淋巴特异性酪氨酸磷酸酶抑制剂的研究进展
- Author:
Peng-ju ZHU
1
;
Xu-ben HOU
1
;
Hao FANG
1
Author Information
1. Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Jinan 250012, China
- Publication Type:REVIEWS
- Keywords:
lymphoid-specific tyrosine phosphatase;
autoimmune disorder;
inhibitor
- From:
Acta Pharmaceutica Sinica
2017;52(5):699-705
- CountryChina
- Language:Chinese
-
Abstract:
Lymphoid-specific tyrosine phosphatase (LYP) is a phosphatase that is encoded by protein tyrosine phosphatase non-receptor type 22 and is mainly distributed in lymphoid. In psychological condition, LYP inhibits T-cell receptor (TCR) signaling in association with C-terminal kinase (CSK). While in pathological condition, mutant LYP dissociates with CSK, which augments the inhibition of TCR signaling and leads to autoimmune diseases. Consequently, LYP is now considered as a new target of type I diabetes, rheumatic arthritis and Graves disease and some other autoimmune disorders. This review mainly focuses on the development of LYP inhibitors in their structures and activities.
